Are COX-2 inhibitors a risk factor for cardiovascular disease?

被引：2
|
作者：
John, S [1 ]
Schmieder, RE [1 ]
机构：
[1] Univ Erlangen Nurnberg, Med Klin 4, D-91054 Erlangen, Germany
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2002年 / 127卷 / 04期
关键词：
D O I：
10.1055/s-2002-19701
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：156 / 159
页数：4
相关论文
共 50 条
  • [1] COX-2 inhibitors and cardiovascular risk
    Funk, Colin D.
    FitzGerald, Garret A.
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2007, 50 (05) : 470 - 479
  • [2] COX-2 Inhibitors and Cardiovascular Risk
    Cannon, Christopher P.
    Cannon, Paul J.
    [J]. SCIENCE, 2012, 336 (6087) : 1386 - 1387
  • [3] Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors
    Debabrata Mukherjee
    Eric J Topol
    [J]. Arthritis Res Ther, 5
  • [4] COX-2 inhibitors in the treatment of cardiovascular disease
    Peterson, JC
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2002, 167 (07) : 738 - 739
  • [5] COX-2 inhibitors: cancer prevention or cardiovascular risk?
    Senior, K
    [J]. LANCET ONCOLOGY, 2005, 6 (02): : 68 - 68
  • [6] Risk of cardiovascular events associated with COX-2 inhibitors
    不详
    [J]. HOSPITAL MEDICINE, 2001, 62 (09): : 577 - 577
  • [7] COX-2 inhibitors and cardiovascular risk - Point and counterpoint
    Mandell, BF
    [J]. CLEVELAND CLINIC JOURNAL OF MEDICINE, 2001, 68 (11) : 957 - 960
  • [8] Cardiovascular Risk Associated With NSAIDs and COX-2 Inhibitors
    Perry, Laura A.
    Mosier, Charles
    Atkins, Ashton
    Minehart, Megan
    [J]. US PHARMACIST, 2014, 39 (03) : 35 - 38
  • [9] Rofecoxib, selective COX-2 inhibitors and cardiovascular risk
    Dhaun, N.
    Maxwell, S. R. J.
    Webb, D. J.
    [J]. JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2005, 35 (02): : 101 - 103
  • [10] Risk of cardiovascular events associated with selective COX-2 inhibitors
    Mukherjee, D
    Nissen, SE
    Topol, EJ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (08): : 954 - 959
12345